



IFW

PATENT  
Attorney Docket No. 056291-5262

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Lee NEWTON <i>et al.</i>	)	Confirmation No.: 6386
	)	
Application No.: 10/537,723	)	Group Art Unit: 1624
	)	
Filed: June 7, 2005	)	Examiner: <i>Unassigned</i>
	)	
For: PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS	)	Date: January 26, 2007
	)	

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed

invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a


**CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R.


§1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**

Date: **January 26, 2007**  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

  
\_\_\_\_\_  
Gregory T. Lowen  
Registration No. 46,882  
Tel. No.: (202) 739-5915  
Fax No.: (202) 739-3001



## **INFORMATION DISCLOSURE CITATION**

~~(Use several sheets if necessary)~~

PTO Form 1449  
January 26, 2007

Attorney Docket No.  
**056291-5262**

Application No.  
10/537,723

Applicants: Lee NEWTON *et al.*

Filing Date: June 7, 2005

Group Art Unit: 1624

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

		<b>Document No.</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Sub-Class</b>	<b>Translation</b>
1.		WO 2004/054986	July 1, 2004	WIPO			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

2. Hannah et al. "Structural studies on bioactive compounds. Part 29: palladium catalysed arylations and alkynylations of sterically hindered immunomodulatory 2-amino-5-halo-4,6-(disubstituted)pyrimidines" *Bioorg Med Chem.* 8(4):739-750 (2000)

3. Hauser et al. "Synthesis of 5-phenyl-4,6-dimethyl-2-pyrimidol and derivatives from the cyclization of urea with 3-phenyl-2,4-pentanedione" *Journal of Organic Chemistry* 18(5): 588-593 (1953)

**Examiner**

### Date Considered

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.